dr. kahl on the utility of tafasitamab/lenalidomide in dlbcl
Published 4 years ago • 249 plays • Length 1:33Download video MP4
Download video MP3
Similar videos
-
1:32
dr. kahl on findings from the l-mind study with tafasitamab in dlbcl
-
1:16
dr. flinn on the utility of tafasitamab in relapsed/refractory dlbcl
-
1:15
dr. abdulhaq on the safety profile of tafasitamab in dlbcl
-
1:36
the use of tafasitamab and lenalidomide in r/r dlbcl
-
1:41
real-world efficacy of tafasitamab lenalidomide in r/r dlbcl & the importance of patient selection
-
1:31
long-term outcomes with tafasitamab plus lenalidomide for r/r dlbcl
-
1:35
long-term follow-up of tafasitamab and lenalidomide in r/r dlbcl
-
2:02
the use of tafasitamab in dlbcl
-
6:37
l-mind trial in relapsed/refractory dlbcl
-
1:42
dr. kahl on adct-402 for relapsed/refractory b-cell non-hodgkin lymphoma
-
1:49
dr. kahl discusses the construction of adcs for lymphoma treatment
-
1:22
dr. burke on the ongoing first-mind trial with tafasitamab in dlbcl
-
1:17
the latest updates on tafasitamab in dlbcl
-
1:25
dr. kahl on remaining challenges in indolent non-hodgkin lymphoma
-
1:05
updates on tafasitamab for the treatment of dlbcl
-
2:50
tafasitamab-lenalidomide in r/r dlbcl: clinical trial results and real-world data
-
4:07
author voices: brad kahl, md
-
1:07
dr. kahl discusses the potential of frontline ibrutinib in mcl
-
2:02
dr. kahl on promising research in chronic lymphocytic leukemia